Manejo clinico y tratamiento de los pacientes con hepatitis B.

Keyphrases

• Adverse Effects 50%
• Adverse Events Profile 50%
• Antigen Carrier 50%
• Barrier Resistance 50%
• Chronic Hepatitis 50%
• Chronic Hepatitis B 100%
• Chronic Hepatitis B Virus 50%
• Cirrhosis 50%
• Entecavir 50%
• First-line Therapy 50%
• Genetic Barrier 50%
• Hepatitis B 100%
• Hepatitis B e Antigen (HBeAg) 50%
• Hepatitis B Surface Antigen (HBsAg) 50%
• Hepatitis B Virus 100%
• Hepatocarcinoma 50%
• Liver Development 50%
• Liver Fibrosis 50%
• Long-term Treatment 50%
• Nucleoside Analogues 100%
• Nucleosides 100%
• Parenteral Administration 50%
• Pegylated Interferon 100%
• Potent Inhibitor 50%
• Serological Evidence 50%
• Tenofovir 50%
• Viral Replication 50%
• World Population 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 33%
• Chronic Hepatitis 33%
• Chronic Hepatitis B 100%
• Entecavir 33%
• Hepatitis B 100%
• Hepatitis B Virus 100%
• Hepatitis B(e) Antigen 33%
• Infection 33%
• Liver Cell Carcinoma 33%
• Liver Cirrhosis 33%
• Liver Fibrosis 33%
• Membrane Antigen 33%
• Nucleoside 66%
• Peginterferon 66%
• Tenofovir 33%